How Germany Built Europe’s Largest Cannabis Market, Regulation First

By Robert Hoban & Aleksandra Vujinović

Spend enough time crossing borders in cannabis policy and the road stops looking linear. Some countries sprint, others stall, and many talk reform without ever building anything real. Germany chose a different route: less spectacle, more structure.

Over the last decade, Germany has undergone one of the most significant cannabis transformations in Europe. What once existed primarily within activist circles, patient communities and legal gray zones has evolved into Europe’s largest medical cannabis market and an emerging adult-use framework around cannabis clubs.

Standing in Berlin this April at ICBC Berlin 2026, the largest and longest-running B2B cannabis event in Europe, that reality became impossible to ignore. More than 5,000 attendees from over 80 countries filled the Estrel Berlin Hotel, moving through corridors that felt less like a trade show and more like a temporary capital of the global cannabis economy. Inside, conversations tracked international supply chains, regulatory frameworks and commercialization strategies. Outside, a compliant on-site consumption lounge operated with the kind of procedural calm that feels almost uniquely German: not rebellious, not performative, simply regulated.

At the ICBC Atrium, in the Grow Pavilion, and across packed meeting rooms, the tone was not speculative anymore. It was infrastructural. Germany, once viewed as a cautious observer in global cannabis reform, was now acting as a gravitational center for policy, capital and compliance.

Days before U.S. marijuana rescheduling discussions moved exactly where many of us on a panel had anticipated, there was discussion in Berlin about what might come next in the American system. But the larger takeaway from Berlin was about recognizing the shift in gravity.

Germany is no longer asking whether cannabis belongs in society. That debate is over. The question now is what kind of system it intends to build around it.

Germany Built the Infrastructure Before the Market

Unlike Canada or several U.S. states, Germany did not begin with retail normalization or dispensary culture. It built a pharmaceutical system first.

Early reform moved through licensed pharmacies, EU-GMP quality standards, and tightly regulated import channels. Cannabis entered the system as medicine before it entered culture, embedded within Germany’s broader narcotics and healthcare frameworks rather than consumer markets.

The 2017 medical cannabis reform marked the first major turning point. Cannabis became available through prescriptions under Germany’s narcotics framework and, in certain cases, could be reimbursed by public health insurers. Access remained bureaucratic, but the foundation was set. Imports increased, pharmacy distribution expanded, and telemedicine platforms slowly emerged.

Then came 2024.

The Cannabis Act (CanG) removed cannabis from the narcotics framework and introduced the MedCanG as a distinct legal structure for medical cannabis. At the same time, home cultivation and cultivation associations were legalized under tightly controlled conditions.

The market response was immediate. Digital prescription systems and telemedicine platforms scaled rapidly, in some cases allowing consultations and approvals within extremely short timeframes. Mail-order pharmacies in urban centers began delivering cannabis products to patients within hours.

Patient numbers reportedly surged from roughly 250,000 to nearly 900,000 in a little over a year. Imports tripled. Market revenues moved toward an estimated €1 billion annually. International producers entered the system, pharmaceutical distributors expanded, and pricing began to decline under increased competition.

According to data published by the German Federal Institute for Drugs and Medical Devices (BfArM) in March 2026, Germany imported a record 201.1 tons of medical cannabis in 2025 alone, firmly establishing it as Europe’s largest medical cannabis market.

But rapid expansion brought political tension. Policymakers began reassessing telemedicine rules, online prescription structures, and reimbursement policies for cannabis flower products. Germany, unlike more liberalized markets, appears intent on controlling the pace of commercialization rather than reacting to it.

Cannabis Clubs and the Controlled Experiment

Germany’s cultivation associations, often called cannabis clubs internationally, represent the country’s most distinct structural innovation.

Unlike Spain’s social club model, Germany’s framework is non-commercial, tightly regulated, and designed around collective cultivation rather than retail access. Consumption inside cultivation associations is prohibited. The focus is production, compliance, and controlled distribution among members.

Up to 500 members may collectively cultivate cannabis for personal use, with each adult permitted up to 50 grams per month.

On paper, it is restrictive. In practice, it is foundational.

The system imposes strict requirements around cultivation limits, membership structures, youth protection measures, security protocols, distribution controls, and advertising restrictions. But within those constraints, an entirely new ecosystem is forming: cultivation technology companies, genetics providers, compliance software platforms, laboratories, and local educational services.

Germany is not building dispensaries. It is building infrastructure.

By mid-2026, more than 836 cultivation association applications had reportedly been filed nationwide, with 413 licenses already granted. Yet implementation varies significantly by federal state, with local authorities interpreting and enforcing the national framework differently.

The law is uniform. The experience is not.

Mary Jane Berlin and the Cultural Arc

The evolution of Mary Jane Berlin reflects this broader transformation.

What began in 2016 as a niche cannabis gathering rooted in subculture has become one of the largest cannabis events in the world. Held June 11–14, 2026 at Messe Berlin, the event drew tens of thousands of attendees and more than 750 exhibitors across nine halls.

The shift was not simply scale. It was legitimacy.

Cannabis in Germany is no longer confined to activist narratives or underground economies. It now sits in the same institutional space as pharmaceuticals, investment conferences, regulatory summits, and international trade fairs.

Regulation, Investment, and the Next Phase

Across ICBC Berlin, one theme repeated itself: Germany is becoming Europe’s central hub for cannabis infrastructure.

Medical imports, pharmaceutical distribution, genetics, compliance systems, and professional services are increasingly concentrated in the German market. Investors from the United States and beyond are now treating Germany not as an emerging opportunity, but as a foundational European entry point.

At the same time, discussions are expanding beyond flower. Extracts, vaporizers, and potentially edibles are part of ongoing policy and industry conversations, even if regulatory clarity remains limited.

The trajectory is toward diversification, but the pace remains controlled.

This reflects a deeper philosophical divide in global cannabis reform. The United States largely pursued commercialization first and regulation second. Germany appears to be doing the inverse: constructing regulatory architecture first, then allowing carefully bounded commercialization to follow.

That difference will define the next decade.

The Future Is Not Loud

Walking through Berlin after ICBC, past train stations and late-night cafés where conference conversations continued in smaller circles, it became clear that Germany’s cannabis story is not about spectacle.

It is about systems.

It is about whether a country can integrate a once-prohibited plant into medicine, commerce, and daily life without destabilizing the institutions that govern it.

Ten years after Mary Jane Berlin first emerged as a subcultural gathering, Germany now stands at a crossroads that feels less like a beginning and more like a consolidation.

The infrastructure is built. The market is forming. The capital is arriving. What remains uncertain is scale.

Years of border-crossing in this industry can make the terrain feel strange and winding. Standing in Berlin, it no longer felt strange. It felt like the beginning of something carefully, deliberately inevitable.

Editor’s note: This article is from external, unpaid contributors. It does not represent IgniteIt’s reporting. It reflects observations from ICBC Berlin in April 2026.